for myocardial injury, due to their higher sensitivity and specificity for diagnosis of myocardial
infraction.
According to Journal of the American Medical Association (JAMA), in 2016, acute coronary
syndrome is estimated as the major cause of morbidity and mortality worldwide. It is also
responsible for over 1 million hospital admissions in the U.S. annually. Increasing incidence of
myocardial infraction (MI) or heart attack, acute coronary syndrome, and consistent development in
cardiac markers by existing market players are some of the factors fueling growth of the cardiac
marker testing devices market. Moreover, high blood pressure, high LDL cholesterol, smoking,
unhealthy diet, diabetes, obesity, physical inactivity, and excessive alcohol consumption are some
other factors which cause coronary heart disease and associated disorders. This in turn, is expected
to drive growth of the global cardiac marker testing devices market in the near future.
According to a report by National Center for Chronic Disease Prevention and Health Promotion
(NCCDPHP), in 2016, around 47% of geriatric population in U.S. have at least one of three major
risk factor of cardiovascular disease (CVD), which includes uncontrolled high blood pressure,
uncontrolled high LDL cholesterol, and smoking. However, controlling these factors could reduce
the risk of heart attack by 80%. BBI Solutions- a developer and manufacturer of raw material and
finished test platforms for the in-vitro diagnostic tests, in 2017 announced to launch myoglobin
antibiotics as a cardiac marker. These cardiac marker have been tested in ELISA assay before using
it in commercial assay procedures and patient’s screening processes. The launch of new cardiac
marker allows expansion of BBI solution’s antibodies portfolio in the global cardiac marker testing
devices market.
For More Information @ https://www.coherentmarketinsights.com/ongoing-insight/cardiac-
marker-testing-devices-market-1039
According to American Heart Association (AHA), around 790,000 people in U.S. have heart attack
every year. Furthermore, an estimated annual incidence of heart attack in the U.S. are around
580,000 cases and 210,000 recurrent cases. According to AHA 2017 report, myocardial infraction
diagnosis cost around US$ 11.5 billion and coronary heart disease cost around US$ 10.4 billion,
were estimated as the most expensive hospital discharge diagnosis. The number of cardiovascular
disease cases is expected to increase to 131.2 million by 2035, accounting to nearly 45% of the total
U.S. population, with expected cost to reach US$ 1.1 trillion, which in turn, is expected to drive
growth of the cardiac marker testing devices market.
Cardiac Marker Testing Devices Market Taxonomy:
By marker type:
•Lactate Dehydrogenase
•Creatine Kinase (CK)
•CK-MM
•CK-MB
•CK-BB
•Myoglobin
•Natriuretic Peptides
•Aspartate Aminotransferase (AST)
•Cardiac Troponin